The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Financial
  • Construction
  • Sports
  • Services

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
  • Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
  • New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Twin Flame Visions Shatters Industry Norms With Breakout Ad Performance A New Era for Spiritual Rea
  • Accelerating Precious Metals Expansion and Digital Asset Innovation Ahead of 2026: Asia Broadband Inc. (Stock Symbol: AABB)
  • SIMM Capital Fund Surpasses $25M Raised and $100M+ in Real Estate Assets
  • Naturism Resurgence (NRE) Announces the World's First Standardised Stigma Measure (SSM) for Naturism
  • London Art Exchange Emerges as a Leading Force in UK Contemporary Art, Elevating Three Artists to Secondary-Market Success

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Super League (N A S D A Q: SLE) Enters Breakout Phase: New Partnerships, Zero Debt & $20 Million Growth Capital Position Company for 2026 Acceleration
  • Finland's Gambling Reform Promises "Single-Click" Block for All Licensed Sites
  • Private Keys Are a Single Point of Failure: Security Advisor Gideon Cohen Warns MPC Technology Is Now the Only Defense for Institutional Custody
  • Compliance Is the Ticket to Entry: Legal Advisor Gabriela Moraes Analyzes RWA Securitization Paths Under Brazil's New Legislation
  • Coalition and CCHR Call on FDA to Review Electroshock Device and Consider a Ban
  • Spark Announces 2025 Design Award Winners
  • NEW Luxury Single-Family Homes Coming Soon to Manalapan - Pre-Qualify Today for Priority Appointments
  • Together We Dance Shines at Newtown Holiday Parade
  • Dominic Pace Returns to the NCIS Franchise With Guest Role on NCIS: Origins
  • Anderson Periodontal Wellness Attends 5th Joint Congress for Ceramic Implantology
  • UK Financial Ltd Completes Full Ecosystem Conversion With Three New ERC-3643 SEC-Ready Tokens As MCAT Deadline Closes Tonight
  • AI Real Estate Company Quietly Building a National Powerhouse: reAlpha Tech Corp. (N A S D A Q: AIRE)
  • Inkdnylon Expands National Uniform Embroidery Services
  • Appliance EMT Expands Appliance Repair Services to Portland, OR and Vancouver, WA
  • Next Week: The World's Best Young Pianists Arrive in Music City for the 2025 Nashville International Chopin Piano Competition
  • Revenue Optics Builds Out Its Dedicated Sales Recruiting Firm with Strategic Addition of Christine Schafer
  • Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
  • Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
  • Flower City Tattoo Convention Draws Record Attendance in Rochester, NY
  • KIKO NATION TOKEN (Official Release)

Popular on PennZone

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 596
  • BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers - 218
  • Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership - 106
  • 5,000 Australians Call for Clarity: NaturismRE's Petition Reaches Major Milestone
  • Corcoran DeRonja Real Estate Welcomes Siobhán Simões to Its Growing Team
  • Heritage At Manalapan - A New Luxury Single Family Home Community Coming Late 2025
  • Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
  • Turbo vs. Experts: Tracking OddsTrader's AI Performance at the NFL's Midpoint
  • The Lashe® Announces Exclusive November Savings for Lash and Beauty Professionals
  • November is Lung Cancer Awareness Month: Screening Saves Aims to Increase Access to Lung Screenings in NC

Similar on PennZone

  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
  • U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
  • Global Innovators Take the Stage at the WorldUpstart Accelerator Showcase in Philadelphia
  • Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
  • MDRN MUSE Expands Insurance Network Coverage to Include Delta Dental & Cigna
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us